Steve trained as a drug discovery scientist through ten years at Pfizer, UK after graduating from University of Wales, Aberystwyth. During this industrial experience he moved from a gene expression expert, into biochemistry, pharmacology and lab safety. He also was familiar with the need for better peptide libraries to hit difficult drug targets, especially ion channels.

After redundancy from Pfizer in 2010 Steve set up Venomtech Ltd to deliver assay ready purified venom peptides to address the difficult targets in drug discovery. Through the first ten years of Venomtech we regularly traded with Europe both as a source of responsibly sourced venomous animals but also supplying venom libraries to European drug discovery and crop science companies. Brexit has been a significant challenge for Venomtech to adapt to as being the only commercial venom lab in the UK there is no trade community or similar companies to look to. In 2020 Venomtech closed a major funding round and this allowed Steve to focus on the Chief Scientific Officer role and thus focus on the venom science and the challenges that entails.